MindWalk Holdings Launches B Cell Llama Platform for Antibody Discovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
MindWalk Holdings "announced B Cell Llama(TM), a platform for the discovery of VHH nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies. Bispecific antibody sales alone are projected to reach US$50 billion by 2030, with the broader cell therapy market adding tens of billions more. B Cell Llama is designed to help partners capture this opportunity with better starting material and AI-guided precision at every step of the discovery process. The announcement is anchored by a study published in Biomacromolecules (American Chemical Society, 2026), conducted by MindWalk in a grant-funded collaboration with Eindhoven University of Technology and Radboud University Medical Center. Three findings from the study illustrate what modular VHH design can achieve: Potency amplified through assembly. Nanobodies displayed in multivalent formats achieved sub-nanomolar potency, 10 to 25 times greater than the same nanobody in monovalent form; Modular reconfiguration defeats resistance. A trivalent VHH construct neutralized variants that escaped all monovalent formats and defeated a pair of approved antibody therapies, demonstrating that rational reassembly of the same building block can restore activity where single agents fail; A potential immune-priming effect. VHH-nanoparticle complexes were preferentially internalized by immune cells associated with long-term immune memory, raising the possibility that certain VHH formats may not only neutralize a target but help the immune system recognize it in the future. The study also produced a finding with direct relevance to AI-guided drug discovery: the molecule with the strongest binding affinity delivered zero functional activity. Binding strength is not a reliable proxy for efficacy. Some conventional discovery workflows depend heavily on binding metrics to rank and select candidates. LensAI(TM) is designed to prioritize function directly."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HYFT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HYFT
Wall Street analysts forecast HYFT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.790
Low
5.00
Averages
5.00
High
5.00
Current: 1.790
Low
5.00
Averages
5.00
High
5.00
About HYFT
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
MindWalk Reports Significant Progress in Drug Development
- Clinical Trial Count: MindWalk's antibody discovery efforts have led to over 20 partner-owned drug programs entering clinical trials, with ten currently in active Phase 1-3 trials, showcasing the company's robust R&D capabilities in biopharmaceuticals.
- Establishing Scientific Standards: With over 400 peer-reviewed publications and patents, MindWalk has established a rare scientific standard in the industry, ensuring a consistent output of clinical-stage assets across multiple therapeutic areas for its partners.
- Biological Intelligence Infrastructure: The HYFT® system and LensAI™ platform, developed as a purpose-built AI architecture, integrate biological pattern recognition technology, enhancing the efficiency and success rate of clinical asset development within MindWalk's antibody discovery engine.
- Strategic Partnerships: MindWalk collaborates with several prominent biopharmaceutical companies, including Annexon Biosciences and argenx, further solidifying its market position and influence in the biopharmaceutical industry.
See More
MindWalk Reports 52% Revenue Growth in Q3
- Significant Revenue Growth: MindWalk Holdings Corp reported a revenue of $4.2 million for Q3, marking a 52% year-over-year increase, indicating strong market performance, particularly with a strategic focus on the North American market.
- Outstanding US Market Performance: The company's US revenue doubled year-over-year to $2.6 million, reflecting MindWalk's successful transition in the North American market, which is expected to further drive future revenue growth.
- Increased R&D Investment: R&D expenses rose to $1.2 million in Q3 from $0.9 million last year, demonstrating the company's ongoing investment in advancing pipeline programs, although this poses pressure on short-term profitability.
- Strong Cash Position: MindWalk ended Q3 with $14.2 million in cash, providing a solid financial foundation for future investments and growth, despite a net loss of $3.9 million, which is a significant improvement from last year's $22 million loss.
See More
MindWalk (HYFT) Q3 2026 Earnings Call Transcript
See More
MindWalk Q3 Earnings Beat Expectations with Revenue Growth
- Earnings Performance: MindWalk Holdings Corp. reported a Q3 GAAP EPS of -$0.08, missing expectations by $0.04, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Surge: The company achieved Q3 revenue of $4.16M, reflecting a 52.4% year-over-year increase, surpassing market expectations by $0.82M, which highlights strong business momentum in a challenging economic environment.
- Market Reaction: Although the EPS fell short of expectations, the significant revenue growth may bolster investor confidence in the company's future performance, potentially leading to a positive impact on its stock price.
- Industry Comparison: Compared to peers like Avino Silver & Gold and Harmony Gold, MindWalk's revenue growth rate demonstrates its competitive position within the industry, although improvements in profitability are necessary to attract more investors.
See More
MindWalk Reports Third Consecutive Quarter of Revenue Growth
- Significant Revenue Growth: MindWalk reported Q3 FY2026 revenue of CAD 4.2 million, a 52% increase year-over-year, demonstrating strong growth momentum in the biotech sector, particularly with a strategic focus on the North American market.
- Outstanding US Market Performance: US revenue reached CAD 2.6 million, doubling from the previous year, reflecting MindWalk's successful expansion in biologics services, thereby enhancing its competitive position in the market.
- First Platform Contract Signed: MindWalk signed a one-year LensAI platform contract with its largest enterprise AI client, marking the company's first recurring revenue agreement, which signifies a transformative shift in its revenue structure.
- New Platform Launch: MindWalk launched the B cell Llama™ nanobody discovery platform aimed at addressing bottlenecks in multispecific antibody development, which is expected to drive future market opportunities exceeding $50 billion.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
MindWalk Reports Significant Progress in Drug Development
- Clinical Trial Count: MindWalk's antibody discovery efforts have led to over 20 partner-owned drug programs entering clinical trials, with ten currently in active Phase 1-3 trials, showcasing the company's robust R&D capabilities in biopharmaceuticals.
- Establishing Scientific Standards: With over 400 peer-reviewed publications and patents, MindWalk has established a rare scientific standard in the industry, ensuring a consistent output of clinical-stage assets across multiple therapeutic areas for its partners.
- Biological Intelligence Infrastructure: The HYFT® system and LensAI™ platform, developed as a purpose-built AI architecture, integrate biological pattern recognition technology, enhancing the efficiency and success rate of clinical asset development within MindWalk's antibody discovery engine.
- Strategic Partnerships: MindWalk collaborates with several prominent biopharmaceutical companies, including Annexon Biosciences and argenx, further solidifying its market position and influence in the biopharmaceutical industry.
See More
MindWalk Reports 52% Revenue Growth in Q3
- Significant Revenue Growth: MindWalk Holdings Corp reported a revenue of $4.2 million for Q3, marking a 52% year-over-year increase, indicating strong market performance, particularly with a strategic focus on the North American market.
- Outstanding US Market Performance: The company's US revenue doubled year-over-year to $2.6 million, reflecting MindWalk's successful transition in the North American market, which is expected to further drive future revenue growth.
- Increased R&D Investment: R&D expenses rose to $1.2 million in Q3 from $0.9 million last year, demonstrating the company's ongoing investment in advancing pipeline programs, although this poses pressure on short-term profitability.
- Strong Cash Position: MindWalk ended Q3 with $14.2 million in cash, providing a solid financial foundation for future investments and growth, despite a net loss of $3.9 million, which is a significant improvement from last year's $22 million loss.
See More
MindWalk (HYFT) Q3 2026 Earnings Call Transcript
See More
MindWalk Q3 Earnings Beat Expectations with Revenue Growth
- Earnings Performance: MindWalk Holdings Corp. reported a Q3 GAAP EPS of -$0.08, missing expectations by $0.04, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Surge: The company achieved Q3 revenue of $4.16M, reflecting a 52.4% year-over-year increase, surpassing market expectations by $0.82M, which highlights strong business momentum in a challenging economic environment.
- Market Reaction: Although the EPS fell short of expectations, the significant revenue growth may bolster investor confidence in the company's future performance, potentially leading to a positive impact on its stock price.
- Industry Comparison: Compared to peers like Avino Silver & Gold and Harmony Gold, MindWalk's revenue growth rate demonstrates its competitive position within the industry, although improvements in profitability are necessary to attract more investors.
See More
MindWalk Reports Third Consecutive Quarter of Revenue Growth
- Significant Revenue Growth: MindWalk reported Q3 FY2026 revenue of CAD 4.2 million, a 52% increase year-over-year, demonstrating strong growth momentum in the biotech sector, particularly with a strategic focus on the North American market.
- Outstanding US Market Performance: US revenue reached CAD 2.6 million, doubling from the previous year, reflecting MindWalk's successful expansion in biologics services, thereby enhancing its competitive position in the market.
- First Platform Contract Signed: MindWalk signed a one-year LensAI platform contract with its largest enterprise AI client, marking the company's first recurring revenue agreement, which signifies a transformative shift in its revenue structure.
- New Platform Launch: MindWalk launched the B cell Llama™ nanobody discovery platform aimed at addressing bottlenecks in multispecific antibody development, which is expected to drive future market opportunities exceeding $50 billion.
See More
